Fermer le menu

Lyon, France – June 15, 2023 – ErVaccine Technologies, a French biotechnology company developing next-generation therapeutic vaccines and cellular immunotherapies in oncology, targeting new families of « unconventional » tumor antigens derived from human endogenous retroviruses (HERVs), announced today the renewing of the Bioinformatics team by appointing talented people skilled in computational biology and machine learning.


Read the press release